Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases.
High growth potential with adequate balance sheet.
Share Price & News
How has Bavarian Nordic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BV3's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BV3 exceeded the German Biotechs industry which returned 7.2% over the past year.
Return vs Market: BV3 exceeded the German Market which returned 14.1% over the past year.
Price Volatility Vs. Market
How volatile is Bavarian Nordic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Bavarian Nordic undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BV3 (€32.7) is trading above our estimate of fair value (€6.5)
Significantly Below Fair Value: BV3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BV3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BV3 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BV3's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BV3 is overvalued based on its PB Ratio (4.1x) compared to the DE Biotechs industry average (3.5x).
How is Bavarian Nordic forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BV3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: BV3 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BV3's is expected to become profitable in the next 3 years.
Revenue vs Market: BV3's revenue (27.8% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: BV3's revenue (27.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BV3's Return on Equity is forecast to be high in 3 years time
How has Bavarian Nordic performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BV3 is currently unprofitable.
Growing Profit Margin: BV3 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BV3 is unprofitable, and losses have increased over the past 5 years at a rate of -39.4% per year.
Accelerating Growth: Unable to compare BV3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BV3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: BV3 has a negative Return on Equity (-21.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Bavarian Nordic's financial position?
Financial Position Analysis
Short Term Liabilities: BV3's short term assets (DKK1.7B) exceed its short term liabilities (DKK226.3M).
Long Term Liabilities: BV3's short term assets (DKK1.7B) exceed its long term liabilities (DKK444.8M).
Debt to Equity History and Analysis
Debt Level: BV3's debt to equity ratio (21.7%) is considered satisfactory.
Reducing Debt: BV3's debt to equity ratio has increased from 8.7% to 21.7% over the past 5 years.
Inventory Level: BV3 has a high level of physical assets or inventory.
Debt Coverage by Assets: BV3's debt is covered by short term assets (assets are 4.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BV3 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BV3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Bavarian Nordic's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BV3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BV3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BV3's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BV3's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BV3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Chaplin (52yo)
Dr. Paul Chaplin MSc, Ph.D. has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S from 2004 ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD1.20M) is about average for companies of similar size in the German market ($USD1.17M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
|CEO & President||5.7yrs||ø8.32m||0.22% DKK2.4m|
|CFO & Executive VP||1.3yrs||ø3.94m||0.00077% DKK8.7k|
|COO & Executive VP||3.1yrs||ø3.63m||no data|
|Executive VP & Chief Business Officer||2.6yrs||ø3.95m||no data|
|Vice President of Investor Relations & Communications||0yrs||no data||no data|
|Executive VP & Chief Commercial Officer||0.08yrs||no data||no data|
Experienced Management: BV3's management team is considered experienced (2.6 years average tenure).
|Independent Director||9.8yrs||ø668.00k||0.11% DKK1.2m|
|Independent Director||7.8yrs||ø608.00k||0.050% DKK567.8k|
|Deputy Chairman||5.8yrs||ø843.00k||0.026% DKK297.0k|
|Independent Director||3.8yrs||ø747.00k||no data|
|Independent Chairman||5.8yrs||ø1.34m||0.050% DKK558.9k|
|Independent Director||2.8yrs||ø633.00k||no data|
|Independent Director||0.8yrs||no data||no data|
Experienced Board: BV3's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bavarian Nordic A/S's company bio, employee growth, exchange listings and data sources
- Name: Bavarian Nordic A/S
- Ticker: BV3
- Exchange: DB
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø8.436b
- Listing Market Cap: ø1.129b
- Shares outstanding: 32.32m
- Website: https://www.bavarian-nordic.com
Number of Employees
- Bavarian Nordic A/S
- Hejreskovvej 10A
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BVNK.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Nov 1998|
|BAVA||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Ordinary Shares||DK||DKK||Nov 1998|
|BV3||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 1998|
|0DPB||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||DKK||Nov 1998|
|BAVAC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||DKK||Nov 1998|
|BVNR.Y||OTCPK (Pink Sheets LLC)||SPONSORED ADR||US||USD||May 2013|
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus. In addition, the company develops MVA-BN HIV, a preclinical stage human immunodeficiency virus (HIV) vaccine candidate; MVA-BN HBV, a preclinical stage hepatitis B vaccine candidate; CV301 that is in various clinical trials for the treatment of bladder, colorecta, and pancreatic and colorectal cancers; and MVA-BN Brachyury that is in Phase II clinical trials for the treatment of chordoma and other metastatic cancers. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Kvistgård, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 20:58|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.